Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

278
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
278
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

240
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
240
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

212
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
212
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

244
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
244
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

859
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
859

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Profile of migraine patients in Middle East and North Africa (MENA) region: a multi-center study.

The journal of headache and pain·2026
Same author

Use of High-Efficacy Therapy in Children With Multiple Sclerosis to Prevent Long-Term Disability.

Neurology·2026
Same author

Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Obstructive Sleep Apnea in Stroke Rehabilitation: A Physical Medicine and Rehabilitation Perspective.

American journal of physical medicine & rehabilitation·2026
Same author

Predicting disease progression in multiple sclerosis with clinically accessible information and technology.

Journal of neurology·2026
Same author

Corrigendum to "Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-study" [Multiple Sclerosis and Related Disorders Vol 106; Feb 2026; Article Number 106885].

Multiple sclerosis and related disorders·2026
Same journal

Neuromyelitis optica spectrum disorder: a 5-year experience in a tertiary hospital in Northern Vietnam.

Multiple sclerosis and related disorders·2026
Same journal

Cell-type-specific Mendelian randomization analysis of brain single-nucleus eQTLs and neuromyelitis optica spectrum disorder risk.

Multiple sclerosis and related disorders·2026
Same journal

Detection of Aquaporin-4 antibody in cerebrospinal fluid in neuromyelitis optica spectrum disorder.

Multiple sclerosis and related disorders·2026
Same journal

Adjunctive gypenosides for acute optic neuritis: A prematurely terminated randomized, double-blind, placebo-controlled pilot trial in a cohort with frequent AQP4-IgG positivity.

Multiple sclerosis and related disorders·2026
Same journal

Genetic and molecular architecture of multiple sclerosis in gulf cooperation council populations: A scoping review and regional precision-neurology perspective.

Multiple sclerosis and related disorders·2026
Same journal

Rising burden and future projections of multiple sclerosis in East Asia: Findings from the global burden of disease study 2021.

Multiple sclerosis and related disorders·2026
See all related articles

Related Experiment Video

Updated: Sep 20, 2025

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.8K

Ocrelizumab for pediatric relapsing multiple sclerosis.

Raed Alroughani1, Malak AlMojel1, Jasem Al-Hashel2

  • 1Division of Neurology, Amiri Hospital, Arabian Gulf Street, Sharq 13041, Kuwait.

Multiple Sclerosis and Related Disorders
|May 28, 2025
PubMed
Summary
This summary is machine-generated.

Ocrelizumab significantly reduced relapses and MRI activity in pediatric multiple sclerosis (MS) patients, demonstrating a safe and effective treatment option. This study highlights its potential for managing pediatric-onset MS (POMS).

Keywords:
KuwaitOcrelizumabPediatric onset multiple sclerosis

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.4K

Related Experiment Videos

Last Updated: Sep 20, 2025

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.8K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.4K

Area of Science:

  • Neurology
  • Immunology
  • Pediatric Medicine

Background:

  • Pediatric-onset multiple sclerosis (POMS) exhibits higher relapse rates and earlier progression to secondary progressive MS compared to adult-onset MS.
  • Ocrelizumab, an anti-CD20 monoclonal antibody, is approved for adult MS but has limited data in POMS.
  • Evaluating Ocrelizumab's efficacy and safety in POMS is crucial due to its aggressive nature.

Purpose of the Study:

  • To assess the effectiveness and safety of Ocrelizumab in treating pediatric-onset multiple sclerosis (POMS).
  • To evaluate relapse rates, MRI activity, and disability progression in POMS patients treated with Ocrelizumab.

Main Methods:

  • Retrospective study of POMS patients (<18 years) treated with Ocrelizumab, with at least one year of follow-up.
  • Primary endpoint: proportion of relapse-free patients.
  • Secondary endpoints: changes in annualized relapse rate (ARR), Expanded Disability Status Scale (EDSS), and MRI activity.

Main Results:

  • 91.7% of POMS patients were relapse-free post-Ocrelizumab treatment, with a significant ARR decrease (1.08 to 0.08, p < 0.001).
  • Minimal MRI activity (4.2%) and stable or improved EDSS scores (75% stabilized, 16.7% improved) were observed.
  • No serious adverse events were reported during the follow-up period.

Conclusions:

  • Ocrelizumab demonstrates significant efficacy in reducing relapses and MRI activity in POMS patients.
  • The treatment was well-tolerated, with no serious side effects reported, indicating a favorable safety profile.
  • Ocrelizumab is a promising and effective therapeutic option for pediatric-onset relapsing-remitting multiple sclerosis (RRMS).